← Back to Search

Anticholinergic

Mecamylamine Challenge for Cognitive Impairment (AMoCC-SCD Trial)

Phase < 1
Waitlist Available
Research Sponsored by Vanderbilt University Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up after administration of second drug challenge, approximately 72 hours
Awards & highlights

AMoCC-SCD Trial Summary

This trial will use a drug to study how attention works in people with Subjective Cognitive Decline. It hypothesizes that those with SCD need more attention activity and that blocking this activity will make their attention worse.

Who is the study for?
This trial is for non-smokers aged 55 or older who feel their memory isn't as good as it used to be but can still score above 25 on a cognitive test (MoCA) and have mild concerns about their memory without serious impairment. People with medical issues that make the drug risky, or major brain conditions like stroke or epilepsy cannot join.Check my eligibility
What is being tested?
The study is testing how an anticholinergic drug called Mecamylamine affects attention in people with slight memory concerns by comparing it to a placebo. Researchers will use EEGs to look at brain activity and tests of attention to see if the drug changes how well participants can focus.See study design
What are the potential side effects?
Mecamylamine may cause side effects such as dizziness, nausea, dry mouth, constipation, blurred vision, and confusion. These are related to its action on the nervous system but will vary from person to person.

AMoCC-SCD Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~after administration of second drug challenge, approximately 72 hours
This trial's timeline: 3 weeks for screening, Varies for treatment, and after administration of second drug challenge, approximately 72 hours for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Peak P1 amplitude for Orienting

Side effects data

From 2014 Phase 3 trial • 21 Patients • NCT00563797
9%
Worsening of Depression
9%
Vomiting/Diarrhea
9%
Relapse to Drinking
100%
80%
60%
40%
20%
0%
Study treatment Arm
Mecamylamine
Placebo

AMoCC-SCD Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Anticholinergic ChallengeExperimental Treatment1 Intervention
All participants will receive oral mecamylamine for 1 day
Group II: Placebo ChallengePlacebo Group1 Intervention
All participants will receive oral placebo for 1 day

Find a Location

Who is running the clinical trial?

Vanderbilt University Medical CenterLead Sponsor
856 Previous Clinical Trials
672,112 Total Patients Enrolled
Paul Newhouse, MDStudy DirectorVanderbilt University Medical Center
4 Previous Clinical Trials
669 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there still vacancies for participants in this investigation?

"Unfortunately, clinicaltrials.gov confirms that this medical study is no longer accepting applicants at the moment; however, 614 other trials are still open for recruitment as of September 6th 2023. This trial was initially advertised on the 1st of September 2023 and has since been updated accordingly."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Attentional Mechanisms in SCD
Kimberly Albert 2024. "Attentional Mechanisms in SCD". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06002477.
~53 spots leftby Jun 2028
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top